Fewer needles, same accuracy? new prostate biopsy study aims to reduce harm

NCT ID NCT05998278

Recruiting now Diagnosis Sponsor: Fujian Medical University Union Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares a personalized biopsy method that uses fewer needle cores to the standard approach for diagnosing prostate cancer. Researchers will enroll 330 men with suspected prostate cancer and randomly assign them to either the personalized or standard biopsy. The goal is to see if the new method maintains high cancer detection while causing fewer complications like bleeding or infection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Personalized optimization of systematic prostate biopsy (procedure)
What this could lead to: If successful, this could offer a safer, more accurate biopsy method for prostate cancer detection, reducing bleeding and infection risks.
What could go wrong: This is a relatively small, early-stage study. The model may not perform as well in broader populations, and reducing cores could miss some cancers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE ADENOCARCINOMA

Contacts and locations

Locations

Department of Urology, Fujian Union Hospital, Fujian Medical University
RECRUITING

Fuzhou, Fujian, 350000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.